Zydus Lifesciences Ltd.

Zydus Lifesciences has entered into First Amendment agreement to the Share Purchase, Subscription and Shareholder’s Agreement (SPSSA) on November 2, 2022 to acquire additional stake of 0.31% on a fully diluted basis in AMP Energy Green Nine (AMP), resulting into aggregate stake of 12.17% on a fully diluted basis in AMP. Earlier, the company had entered into Share Purchase, Subscription and Shareholder’s Agreement to acquire upto 11.86% stake on a fully diluted basis in AMP Energy Green Nine.

In line with the Company’s commitment to enhance the share of renewable power source in its operation and to comply with regulatory requirement for being a captive user under Electricity Laws, 2003, the Company will acquire up to 12.17% stake, in one or more tranches, on fully diluted basis in AMP throughout the term of the definitive agreements i.e., Power Purchase Agreement, SPSSA and First Amendment Agreement to SPSSA.

Zydus Lifesciences (formerly known as Cadila Healthcare) is an India-based pharmaceutical company.